肝脏FDG摄取增强可提升早期PET/CT对弥漫性大B细胞淋巴瘤CD19靶向CAR-T细胞治疗的预后价值
该回顾性分析纳入30例接受CAR-T治疗的侵袭性B细胞淋巴瘤患者,评估PET30代谢缓解与肝脏FDG摄取变化(Delta-Liver-SUVmean)对无进展生存(PFS)的预测价值。结果显示PET30-nCR和Delta-Liver-SUVmean下降均与肿瘤进展高风险相关(HR分别为4.79和3.99),两者联合可区分极低、中、极高复发风险组(PFS分别为未达到、7.5个月、1.5个月)。
要点
- CAR-T前LDH是多因素分析中最强的PFS预测因子。
- PET30-CR组中28.6%患者最终进展,PET30-nCR组75%复发。
- PET30-nCR与Delta-Liver-SUVmean下降分别与肿瘤进展高风险相关(HR 4.79和3.99)。
核心结论
- 除PET30代谢缓解外,Delta-Liver-SUVmean的纵向代谢变化可预测CAR-T疗效,结果可能指导旨在增强CAR-T疗效的早期干预研究,尤其针对极高危患者。
研究设计与样本
- 回顾性分析30例接受CD19-CAR-T治疗的侵袭性B细胞淋巴瘤患者。
主要发现
- CAR-T前LDH是多因素分析中最强的PFS预测因子。
- PET30-CR的14例患者中10例(71.4%)保持疾病缓解,PET30-nCR的16例患者中12例(75%)复发。
- PET30-CR患者中28.6%最终进展。
- PET30-nCR与Delta-Liver-SUVmean下降均与肿瘤进展高风险相关(HR分别为4.79和3.99)。
- PET30与Delta-Liver-SUVmean联合可识别极低、中、极高复发风险组(PFS分别为未达到、7.5个月、1.5个月)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite revolutionary efficacy of CD19-CAR-T cell therapy (CAR-T) in aggressive B cell lymphoma, many patients still relapse mostly early. In early failure, distinct drugs support CAR-T which makes reliable and early prediction of imminent relapse/refractoriness critical. A complete metabolic remission (CR) on Fluor-18-Deoxyglucose (FDG) Positron-Emission-Computed Tomography (PET) 30 days after CAR-T (PET30) strongly predicts progression-free survival (PFS), but still fails in a relevant proportion of patients. We aimed to identify additional routine parameters in PET evaluation to enhance CAR-T response prediction. RESULTS: Thirty patients with aggressive B cell lymphoma treated with CAR-T were retrospectively analyzed. Pre-CAR-T, LDH was the strongest PFS-predictor also by multivariate analysis. Post-CAR-T, 10 out of 14 patients (71.4%) with PET30-CR remained in disease remission, while 12 out of 16 patients (75%) with incomplete metabolic remission (PET30-nCR) relapsed after CAR-T. 28.6% of patients with PET30-CR ultimately progressed. Change of liver FDG-uptake from baseline to day30 (Delta-Liver-SUVmean) was identified as an independent biomarker for response. PET30-nCR and a decrease of Delta-Liver-SUVmean were associated with a high risk of tumor progression (HR 4.79 and 3.99, respectively). The combination of PET30 and Delta-Liver-SUVmean identified patients at very low, at intermediate and at very high risk of relapse (PFS not reached, 7.5 months, 1.5 months, respectively). CONCLUSION: Additionally to PET30 metabolic remission, longitudinal metabolic changes in Delta-Liver-SUVmean predicted CAR-T efficiency. Our results may guide early intervention studies aiming to enhance CAR-T particularly in the very high-risk patients.
引用
- Beck M, Blumenberg V, Bücklein VL, et al. Liver-FDG-uptake augments early PET/CT prognostic value for CD19-targeted CAR-T cell therapy in diffuse large B cell lymphoma. EJNMMI Res. 2025. PMID: 40095158. doi:10.1186/s13550-025-01201-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。